Introduction to Acute Migraine Therapy Outcomes

Clinicians have traditionally relied on triptans as the first-line treatment for migraine attacks. However, the emergence of gepants provides a newer, non-vasoconstrictive alternative for patients. Researchers recently conducted the HeAD-US study to evaluate real-world acute migraine therapy outcomes by comparing these two medication classes. This cross-sectional analysis provides essential data for healthcare providers seeking to optimize patient care in clinical practice.

The HeAD-US Study Methodology

The study leveraged data from the Migraine Buddy application, involving over 1,500 participants who used either gepants or triptans. Researchers focused on two primary metrics: 2-hour pain freedom (2hPF) and 24-hour pain relief (24hPR). Furthermore, they analyzed various demographic and clinical predictors to see how they influenced treatment success. This approach offers a broad view of how these drugs perform outside the controlled environment of traditional clinical trials.

Comparing 2-Hour Freedom and 24-Hour Relief

The results showed that both triptans and gepants achieved similar rates of 2-hour pain freedom. Nevertheless, a significant difference emerged when looking at sustained relief. Specifically, gepant users had 36% higher odds of achieving 24-hour pain relief compared to those using triptans. This finding suggests that while both classes work quickly, gepants may offer more durable acute migraine therapy outcomes for many patients.

Predictors of Treatment Success

Several clinical factors influenced the likelihood of a positive response. For instance, high migraine symptom severity and severe pain intensity reduced the odds of achieving 2-hour pain freedom. Additionally, patients with chronic migraine or high-frequency episodic migraine faced more challenges in achieving adequate relief. Consequently, comorbid treatment burden and high disability remain significant hurdles in managing acute attacks effectively across both medication classes.

Clinical Implications and Personalized Care

These findings highlight the potential benefits of gepants for patients who require sustained relief. Moreover, the study emphasizes that clinical features like headache frequency and disability are vital predictors of how a patient will respond to therapy. While triptans remain effective, the superior 24-hour outcomes associated with gepants might inform a more personalized selection of therapy. Larger head-to-head clinical trials will be necessary to definitively confirm these real-world observations.

Frequently Asked Questions

Which medication class provides better long-term relief during a migraine attack?

According to the HeAD-US study, gepants demonstrated a significant advantage over triptans for 24-hour pain relief, even though both performed similarly at the 2-hour mark.

What factors can predict a poor response to acute migraine treatment?

High symptom severity, frequent attacks, and severe migraine-related disability are major predictors that often lead to reduced treatment success regardless of the medication used.

Are gepants safer for all migraine patients?

Gepants are non-vasoconstrictive, making them a suitable alternative for patients who have contraindications to triptans, such as cardiovascular issues, though clinicians should always assess individual patient needs.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or establish a doctor-patient relationship. Always seek the advice of a qualified healthcare provider regarding any medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Teichrow D et al. Comparative analysis of real-world acute prescription migraine therapy outcomes: Insights from the HeAD-US study. Headache. 2026 May 04. doi: 10.1111/head.70113. PMID: 42077178.

2. Lipton RB et al. Real-world effectiveness of ubrogepant versus triptans: Results from the UNIVERSE II study. American Headache Society Annual Scientific Meeting. 2024.

3. Chiang CC et al. Simultaneous Comparisons of 25 Acute Migraine Medications Based on 10 Million Users' Self-Reported Records From a Smartphone Application. Neurology. 2024;102(1).